Lexeo Therapeutics (LXEO) Accounts Payables (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Accounts Payables data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 72.16% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (down 72.16% YoY), and the FY2025 full-year result was $4.9 million, down 24.33% from the prior year.
• Accounts Payables retreated to $3.3 million in Q1 2026, from $4.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $20.0 million in Q2 2025 to a low of $2.7 million in Q3 2023.
• A 5-year average of $6.6 million and a median of $4.8 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 247.35% in 2025 and tumbled 72.16% in 2026, its largest moves.
• Tracing LXEO's Accounts Payables over 5 years: stood at $2.7 million in 2022, then soared by 41.67% to $3.8 million in 2023, then jumped by 69.14% to $6.4 million in 2024, then slipped by 24.33% to $4.9 million in 2025, then tumbled by 31.32% to $3.3 million in 2026.
• Business Quant data shows LXEO's Accounts Payables at $3.3 million in Q1 2026, $4.9 million in Q4 2025, and $4.7 million in Q3 2025.